Uncategorized
Eylea approved in Europe for visual impairment due to myopic choroidal neovascularization
Eylea has received approval in Europe for the treatment of visual impairment secondary to myopic choroidal neovascularization, Regeneron announced in a press release. Eylea (aflibercept) is currently approved in Europe for the treatment of patients with neovascular age-related macular degeneration, visual impairment due to diabetic macular edema and visual impairment due to macular edema secondary to retinal vein occlusion.